Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 2893
Fibromyalgia is a common condition characterized by long-term, body-wide pain and tender points in joints, muscles, tendons, and other soft tissues. Fibromyalgia has also been linked to fatigue, morning stiffness, sleep problems, headaches, numbness in hands and feet, depression, and anxiety.
IPSCIO Record ID: 2616
IPSCIO Record ID: 1336
The due diligence requirements of the exclusive License Agreement were amended in April of 2010 and further amended by a Non-Disturbance Agreement that was signed with the Licensor, the Licensee and Meda.
IPSCIO Record ID: 28675
Pursuant to the Licensor's License Agreement with McLean Hospital, the Licensor paid 15% of the payment, that was netted against the revenues received from the Licensee.
The Licensor is also entitled to additional milestone payments upon filing of an NDA with the U.S. FDA for oral flupirtine for fibromyalgia and upon marketing approval.
The Sublicense Agreement provides that the Licensee will assume all future development costs for the commercialization of oral flupirtine for fibromyalgia.
IPSCIO Record ID: 1242
IPSCIO Record ID: 797
The grant of each License hereunder includes the right to grant subLicenses to Related Companies.
Trademarks mean Feldetrexâ„¢, including US Trademark Application No. 77/601,101 and any identical marks later filed in countries other than the United States of America.
Feldetrexâ„¢ drug is a proprietary combination of generic medications which is believed to reduce the symptomatology of Multiple Sclerosis, Fibromyalgia, and Traumatic Brain Injury.
Multiple Sclerosis is a chronic, progressive illness that affects the nerves in the brain, spinal cord, and other parts of the central nervous system.
Fibromyalgia (FM or FMS) is characterized by chronic widespread pain and allodynia (a heightened and painful response to pressure). Its exact cause is unknown but is believed to involve psychological, genetic, neurobiological and environmental factors.
Licensee shall prominently use the Trademark on Licensed Products.
IPSCIO Record ID: 5599
IPSCIO Record ID: 203476
Licensee hereby grants to Licensor during the R&D Term a non-exclusive, non-sublicensable, non-transferable license to the Licensee for use by Licensor only for the performance of its obligations under this Agreement. Licensor agrees that it shall not use the Licensee for any other purposes.
Licensee Patents shall mean, to the extent necessary or useful for the development of Reformulated Products or New Products or otherwise for purposes of the R&D Plan, (a) all foreign and domestic (i) patents issued or existing as of the Effective Date which Licensee Controls; (ii) patents issuing from patent applications that are pending as of the Effective Date.
Reformulated Product shall mean any Product which is developed by Licensor under this Agreement and contains milnacipran in a formulation that is different than the Existing Product, but that does not meet the criteria for a New Product.
Milnacipran is immediate release formulation in capsule form containing 25 mg and 50 mg of milnacipran and the existing slow release fo1mulation containing 120 mg of milnacipran, as set forth in PCT published international application WO 98/08495.